Volume 134 Issue 25 | Blood | American Society of Hematology
Read the current issue of Blood.
Related Articles
Restarting Teclistamab and Talquetamab after Prolonged Dose Delay May Not Require Re-Step-up Dosing
Carlyn R Tan, Alice X Wang, David Nemirovsky, Andriy Derkach, Tala Shekarkhand, Issam S. Hamadeh, Kylee H. Maclachlan, Malin L Hultcrantz, Hani Hassoun, Sh
Arsenic and old FLT3
FLT3-internal tandem duplication (FLT3-ITD) mutations are common in acute promyelocytic leukemia (APL) and render the disease more difficult to manage or c
The chromatin accessibility landscape of pediatric AML
In this issue of Blood, Cui et al dissect the single-cell and clonally resolved chromatin accessibility landscape of pediatric acute myeloid leukemia (pAML
Novel mechanisms of resistance in CLL: variant BTK mutations in second-generation and noncovalent BTK inhibitors
There are now multiple Bruton tyrosine kinase (BTK) inhibitors available, all sharing the common mechanism of blocking enzymatic activity, while exhibiting
Inaticabtagene autoleucel in adult relapsed or refractory B-cell acute lymphoblastic leukemia
Key PointsInati-cel can induce high and durable responses in patients with R/R B-ALL, with a best ORR of 85.4% and a median DOR of 20.7 months.At…
Therapy for MYD88 L265P DLBCL
In this issue of Blood, Li et al report their finding that the small molecule compound lasalocid A specifically targets mutated MYD88 L265P protein in diff
Peripheral neuropathy in the phase 3 ASPEN study of Bruton tyrosine kinase inhibitors for Waldenström macroglobulinemia
Key PointsIn patients with WM treated with Bruton tyrosine kinase inhibitors, major response was associated with PN symptom resolution.Patients whose PN sy
Elderly Patients With BPDCN Respond Well to Venetoclax, Bortezomib, Dexamethasone Combination | ASH Clinical News | American Society of Hematology
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. Patients with the rare, aggressive hematologic malignancy blastic plasmacytoid dendritic cell neoplasm (BPDCN)…
